2018. Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 2, S1 (Feb. 2018), S22. DOI:https://doi.org/10.25251/skin.2.supp.22.